Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Summit Therapeutics (SMMT) Other Accumulated Expenses (2019 - 2026)

Summit Therapeutics filings provide 8 years of Other Accumulated Expenses readings, the most recent being $1.1 million for Q1 2026.

  • Quarterly Other Accumulated Expenses rose 51.25% to $1.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Mar 2026, up 51.25% year-over-year, with the annual reading at $2.3 million for FY2025, 27.05% up from the prior year.
  • Other Accumulated Expenses hit $1.1 million in Q1 2026 for Summit Therapeutics, down from $2.3 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $2.3 million in Q4 2025 and bottomed at $209000.0 in Q3 2022.
  • Average Other Accumulated Expenses over 5 years is $941352.9, with a median of $759000.0 recorded in 2025.
  • The largest annual shift saw Other Accumulated Expenses plummeted 79.71% in 2022 before it skyrocketed 150.63% in 2024.
  • Summit Therapeutics' Other Accumulated Expenses stood at $662000.0 in 2022, then grew by 8.31% to $717000.0 in 2023, then skyrocketed by 150.63% to $1.8 million in 2024, then rose by 27.05% to $2.3 million in 2025, then crashed by 49.72% to $1.1 million in 2026.
  • Per Business Quant, the three most recent readings for SMMT's Other Accumulated Expenses are $1.1 million (Q1 2026), $2.3 million (Q4 2025), and $2.0 million (Q3 2025).